Healthcare entity

ACP-101

Technology

Every one of those 1 sits in a single category, market-trends. Acadia Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.2 for the same window.

Last mentioned: Feb 27, 2026

Entity pulse

Recent coverage · ACP-101

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about ACP-101

Every one of those 1 sits in a single category, market-trends. Acadia Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3.2 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.7. We currently track 1 Healthcare story that mention ACP-101, all published on February 27, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering ACP-101. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Fiscal Milestone

    ACADIA reports record quarterly revenue and achieves annual GAAP profitability.

  2. Trial Setback

    Phase 3 ADVANCE-2 trial for pimavanserin in schizophrenia fails to meet primary endpoint.

  3. Commercial Launch

    Daybue officially enters the U.S. market with strong initial uptake.

  4. FDA Approval

    Daybue (trofinetide) approved as the first treatment for Rett syndrome.

Stories mentioning ACP-101 1

ACP-101 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.